Haemodialysis-associated amyloidosis
| Haemodialysis-associated amyloidosis | |
|---|---|
| Classification and external resources | |
| Specialty | endocrinology |
| ICD-10 | E85.3 |
| ICD-9-CM | 277.3 |
| eMedicine | med/3384 |
Haemodialysis-associated amyloidosis is a form of amyloidosis associated with chronic kidney failure.[1]
Presentation
Long-term haemodialysis results in a gradual accumulation of β2 microglobulin, a serum protein, in the blood.[2] It accumulates because it is unable to cross the dialysis filter.
Affected individuals usually present after 5 years of dialysis rarely before that. The tendency of haemodialysis-associated amyloidosis is to be articular in general affecting the joints.
Prevention
Low copper dialysis is theorized to prevent or delay onset.[3]
See also
References
- ↑ Miyata T, Oda O, Inagi R, et al. (September 1993). "beta 2-Microglobulin modified with advanced glycation end products is a major component of hemodialysis-associated amyloidosis". J. Clin. Invest. 92 (3): 1243–52. doi:10.1172/JCI116696. PMC 288264. PMID 8376584.
- ↑ Rapini, Ronald P.; Bolognia, Jean L.; Jorizzo, Joseph L. (2007). Dermatology: 2-Volume Set. St. Louis: Mosby. ISBN 1-4160-2999-0.
- ↑ "BU Amyloid Treatment & Research Program".
| ||||||||||||||||||||||||||||||||
This article is issued from Wikipedia - version of the Tuesday, September 01, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.